Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later

IF 3.7 3区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Research in Social & Administrative Pharmacy Pub Date : 2024-04-11 DOI:10.1016/j.sapharm.2024.04.005
Mark A. Strand , Oliver Frenzel
{"title":"Revisiting the opioid and naloxone education (ONE) program: Program evaluation using the RE-AIM model four years later","authors":"Mark A. Strand ,&nbsp;Oliver Frenzel","doi":"10.1016/j.sapharm.2024.04.005","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The Opioid and Naloxone Education (ONE) Program focuses on community pharmacy-based patient screening and interventions to improve population health with regard to opioid use. The purpose of this paper is to reevaluate the ONE Program performance using the RE-AIM model, in comparison to the review performed in 2019.</p></div><div><h3>Methods</h3><p>The program performance of the ONE Program was evaluated from January 1, 2021 to December 31, 2022 was evaluated using the five domains of the RE-AIM model. Reach was defined as the proportion of patients receiving opioid prescriptions who completed the screening. Efficacy was defined as the proportion of individuals identified as at risk who received a pharmacist intervention. Adoption was defined as the proportion of community pharmacies who enrolled in the ONE Program. Implementation was defined as the proportion of pharmacies that enrolled that provided at least five patient screenings. Maintenance was defined as the proportion of pharmacies that completed at least one screening three months. These results were compared against evaluation of the program from October 12, 2018 to June 1, 2019.</p></div><div><h3>Results</h3><p>Approximately 7.28 % of patients receiving opioid prescriptions were screened for risk of opioid misuse and accidental overdose (Reach). Of the patients screened, 97.4 % of patients at risk for opioid misuse or accidental overdose received a pharmacist-led intervention (Efficacy). Additionally, 49.6 % of the pharmacist that enrolled in the ONE Program completed at least five screenings (79 %) and of those, 86.4 % maintained the program three months later.</p></div><div><h3>Conclusions</h3><p>In years four and five of implementation, the ONE Program demonstrated improvement in four of the five domains of the RE-AIM model compared to years one and two. However, Reach declined over time. This reevaluation has demonstrated the importance of longitudinal program assessment, and the possibility of improved program performance over time.</p></div>","PeriodicalId":48126,"journal":{"name":"Research in Social & Administrative Pharmacy","volume":"20 7","pages":"Pages 648-653"},"PeriodicalIF":3.7000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Research in Social & Administrative Pharmacy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1551741124001190","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Objective

The Opioid and Naloxone Education (ONE) Program focuses on community pharmacy-based patient screening and interventions to improve population health with regard to opioid use. The purpose of this paper is to reevaluate the ONE Program performance using the RE-AIM model, in comparison to the review performed in 2019.

Methods

The program performance of the ONE Program was evaluated from January 1, 2021 to December 31, 2022 was evaluated using the five domains of the RE-AIM model. Reach was defined as the proportion of patients receiving opioid prescriptions who completed the screening. Efficacy was defined as the proportion of individuals identified as at risk who received a pharmacist intervention. Adoption was defined as the proportion of community pharmacies who enrolled in the ONE Program. Implementation was defined as the proportion of pharmacies that enrolled that provided at least five patient screenings. Maintenance was defined as the proportion of pharmacies that completed at least one screening three months. These results were compared against evaluation of the program from October 12, 2018 to June 1, 2019.

Results

Approximately 7.28 % of patients receiving opioid prescriptions were screened for risk of opioid misuse and accidental overdose (Reach). Of the patients screened, 97.4 % of patients at risk for opioid misuse or accidental overdose received a pharmacist-led intervention (Efficacy). Additionally, 49.6 % of the pharmacist that enrolled in the ONE Program completed at least five screenings (79 %) and of those, 86.4 % maintained the program three months later.

Conclusions

In years four and five of implementation, the ONE Program demonstrated improvement in four of the five domains of the RE-AIM model compared to years one and two. However, Reach declined over time. This reevaluation has demonstrated the importance of longitudinal program assessment, and the possibility of improved program performance over time.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
重新审视阿片类药物和纳洛酮教育(ONE)计划:四年后使用 RE-AIM 模型进行项目评估。
目的阿片类药物和纳洛酮教育(ONE)计划侧重于以社区药房为基础的患者筛查和干预,以改善阿片类药物使用方面的人群健康状况。本文旨在使用 RE-AIM 模型重新评估 ONE 计划的绩效,并与 2019 年进行的审查进行对比。方法使用 RE-AIM 模型的五个领域对 2021 年 1 月 1 日至 2022 年 12 月 31 日期间 ONE 计划的绩效进行评估。覆盖率定义为接受阿片类药物处方的患者中完成筛查的比例。疗效是指接受药剂师干预的高危人群比例。采用率是指加入 ONE 计划的社区药房比例。实施率是指加入计划并提供至少五次患者筛查的药房比例。保持率是指三个月内至少完成一次筛查的药房比例。这些结果与 2018 年 10 月 12 日至 2019 年 6 月 1 日的计划评估结果进行了比较。结果约有 7.28% 接受阿片类药物处方的患者接受了阿片类药物滥用和意外过量风险筛查 (Reach)。在接受筛查的患者中,97.4% 有滥用阿片类药物或意外用药过量风险的患者接受了药剂师指导的干预(有效性)。此外,49.6% 报名参加 ONE 计划的药剂师至少完成了五次筛查(79%),其中 86.4% 的药剂师在三个月后继续参加该计划。然而,随着时间的推移,Reach 有所下降。此次重新评估证明了纵向计划评估的重要性,以及随着时间的推移计划绩效得到改善的可能性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Research in Social & Administrative Pharmacy
Research in Social & Administrative Pharmacy PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH-
CiteScore
7.20
自引率
10.30%
发文量
225
审稿时长
47 days
期刊介绍: Research in Social and Administrative Pharmacy (RSAP) is a quarterly publication featuring original scientific reports and comprehensive review articles in the social and administrative pharmaceutical sciences. Topics of interest include outcomes evaluation of products, programs, or services; pharmacoepidemiology; medication adherence; direct-to-consumer advertising of prescription medications; disease state management; health systems reform; drug marketing; medication distribution systems such as e-prescribing; web-based pharmaceutical/medical services; drug commerce and re-importation; and health professions workforce issues.
期刊最新文献
Concordance between pharmacy dispensing and electronic monitoring data of direct oral anticoagulants - A secondary analysis of the MAAESTRO study. Development and validation of a predictive scoring model for risk stratification of tuberculosis treatment interruption. The effects of free prescriptions on community pharmacy selection: A discrete choice experiment. A graphical model to make explicit pharmacist clinical reasoning during medication review. Developing and validating development goals towards transforming a global framework for pharmacy practice.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1